Eli Lilly struck multiple genetic‑medicine deals: it secured global rights to MeiraGTx’s AAV‑AIPL1 retinal gene therapy for LCA4 and signed a large collaboration with SanegeneBio worth up to $1.2 billion to develop tissue‑selective RNAi therapeutics for metabolic diseases. Lilly also deepened existing AI discovery ties, expanding partnerships that span gene therapy, RNAi delivery platforms and computational drug design. The agreements give Lilly late‑stage gene therapy rights and bolster its RNAi delivery capabilities, aligning with the company’s aggressive metabolic and ophthalmology strategy. The deals combine Lilly’s development and commercial footprint with partners’ platform technologies, signaling Big Pharma’s continued appetite for acquiring differentiated genetic modalities and tissue‑targeting delivery mechanisms.